These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 31494973)

  • 21. Community-based trial of a triple-combination agent for the treatment of facial melasma.
    Grimes P; Kelly AP; Torok H; Willis I
    Cutis; 2006 Mar; 77(3):177-84. PubMed ID: 16610738
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of Refractory Melasma in Asians With the Picosecond Alexandrite Laser.
    Polnikorn N; Tanghetti E
    Dermatol Surg; 2020 Dec; 46(12):1651-1656. PubMed ID: 32932271
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Study of oral tranexamic acid, topical tranexamic acid, and modified Kligman's regimen in treatment of melasma.
    Sahu PJ; Singh AL; Kulkarni S; Madke B; Saoji V; Jawade S
    J Cosmet Dermatol; 2020 Jun; 19(6):1456-1462. PubMed ID: 32346962
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of 755-nm picosecond alexandrite laser versus 1064-nm Q-switched Nd:YAG laser for melasma: A randomized, split-face controlled, 2-year follow-up study.
    Zhou Y; Li Y; Hamblin MR; Wen X
    Lasers Surg Med; 2024 Mar; 56(3):263-269. PubMed ID: 38282099
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preventing melasma recurrence: prescribing a maintenance regimen with an effective triple combination cream based on long-standing clinical severity.
    Arellano I; Cestari T; Ocampo-Candiani J; Azulay-Abulafia L; Bezerra Trindade Neto P; Hexsel D; Machado-Pinto J; Muñoz H; Rivitti-Machado MC; Sittart JA; Trindade de Almeida AR; Rego V; Paliargues F; Marques-Hassun K
    J Eur Acad Dermatol Venereol; 2012 May; 26(5):611-8. PubMed ID: 21623930
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of 755-nm picosecond alexandrite laser with topical tranexamic acid versus laser monotherapy for melasma and facial rejuvenation: a multicenter, randomized, double-blinded, split-face study in Chinese patients.
    Li Y; Yao C; Zhang H; Li L; Song Y
    Lasers Med Sci; 2022 Sep; 37(7):2879-2887. PubMed ID: 35501519
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of a fractional picosecond 1,064 nm laser for the treatment of dermal and mixed type melasma.
    Chalermchai T; Rummaneethorn P
    J Cosmet Laser Ther; 2018 Jun; 20(3):134-139. PubMed ID: 29020467
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of a new triple-combination agent for the treatment of facial melasma.
    Taylor SC; Torok H; Jones T; Lowe N; Rich P; Tschen E; Menter A; Baumann L; Wieder JJ; Jarratt MM; Pariser D; Martin D; Weiss J; Shavin J; Ramirez N
    Cutis; 2003 Jul; 72(1):67-72. PubMed ID: 12889718
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sequential treatment with triple combination cream and intense pulsed light is more efficacious than sequential treatment with an inactive (control) cream and intense pulsed light in patients with moderate to severe melasma.
    Goldman MP; Gold MH; Palm MD; Colón LE; Preston N; Johnson LA; Gottschalk RW
    Dermatol Surg; 2011 Feb; 37(2):224-33. PubMed ID: 21269349
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of a picosecond 755-nm alexandrite laser combined with topical tranexamic acid in the treatment of melasma.
    Zhou N; Tao J; Yi Z; Wu L; Liu Z; Yang B
    J Cosmet Dermatol; 2024 Nov; 23(11):3579-3584. PubMed ID: 39234928
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of a novel diffractive lens array using a picosecond 755 nm alexandrite laser for treatment of wrinkles.
    Weiss RA; McDaniel DH; Weiss MA; Mahoney AM; Beasley KL; Halvorson CR
    Lasers Surg Med; 2017 Jan; 49(1):40-44. PubMed ID: 27681221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of a fixed combination of hydroquinone/tretinoin/fluocinolone cream compared with hydroquinone alone in the treatment of melasma.
    Cestari T; Adjadj L; Hux M; Shimizu MR; Rives VP
    J Drugs Dermatol; 2007 Feb; 6(2):153-60. PubMed ID: 17373174
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A split-face study: comparison of picosecond alexandrite laser and Q-switched Nd:YAG laser in the treatment of melasma in Asians.
    Lee MC; Lin YF; Hu S; Huang YL; Chang SL; Cheng CY; Chang CS
    Lasers Med Sci; 2018 Nov; 33(8):1733-1738. PubMed ID: 29732522
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of a 755-nm picosecond laser and hydroquinone 2% cream versus hydroquinone 2% cream alone for the treatment of melasma: A randomized, split-face, and controlled trial.
    Manuskiatti W; Yan C; Gulfan MCB; Techapichetvanich T; Wanitphakdeedecha R
    Lasers Surg Med; 2022 Dec; 54(10):1245-1250. PubMed ID: 36345697
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of a hydroquinone/tretinoin/fluocinolone acetonide cream combination in treating melasma in the United States.
    Alikhan A; Daly M; Wu J; Balkrishnan R; Feldman SR
    J Dermatolog Treat; 2010 Sep; 21(5):276-81. PubMed ID: 20055711
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Melasma treatment with pulsed-dye laser and triple combination cream: a prospective, randomized, single-blind, split-face study.
    Passeron T; Fontas E; Kang HY; Bahadoran P; Lacour JP; Ortonne JP
    Arch Dermatol; 2011 Sep; 147(9):1106-8. PubMed ID: 21931054
    [No Abstract]   [Full Text] [Related]  

  • 37. A comparison of triple combination cream and hydroquinone 4% cream for the treatment of moderate to severe facial melasma.
    Ferreira Cestari T; Hassun K; Sittart A; de Lourdes Viegas M
    J Cosmet Dermatol; 2007 Mar; 6(1):36-9. PubMed ID: 17348994
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A large 12-month extension study of an 8-week trial to evaluate the safety and efficacy of triple combination (TC) cream in melasma patients previously treated with TC cream or one of its dyads.
    Torok H; Taylor S; Baumann L; Jones T; Wieder J; Lowe N; Jarret M; Rich P; Pariser D; Tschen E; Martin D; Menter A; Weiss J
    J Drugs Dermatol; 2005; 4(5):592-7. PubMed ID: 16167418
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A histological examination for skin atrophy after 6 months of treatment with fluocinolone acetonide 0.01%, hydroquinone 4%, and tretinoin 0.05% cream.
    Bhawan J; Grimes P; Pandya AG; Keady M; Byers HR; Guevara IL; Colón LE; Johnson LA; Gottschalk R
    Am J Dermatopathol; 2009 Dec; 31(8):794-8. PubMed ID: 19755910
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Investigator-Blinded, Single-Center Study to Evaluate the Efficacy and Tolerability of a 4% Hydroquinone Skin Care System Plus 0.02% Tretinoin Cream in Mild-to-Moderate Melasma and Photodamage.
    Rendon M; Dryer L
    J Drugs Dermatol; 2016 Apr; 15(4):466-75. PubMed ID: 27050702
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.